+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Complement Inhibitors Market by Therapeutic Application (Atypical Hemolytic Uremic Syndrome, Hereditary Angioedema, Paroxysmal Nocturnal Hemoglobinuria), Mechanism of Action (C1 Inhibitors) - Global Forecast 2025-2030- Product Image
Oral Complement Inhibitors Market by Therapeutic Application (Atypical Hemolytic Uremic Syndrome, Hereditary Angioedema, Paroxysmal Nocturnal Hemoglobinuria), Mechanism of Action (C1 Inhibitors) - Global Forecast 2025-2030- Product Image
New

Oral Complement Inhibitors Market by Therapeutic Application (Atypical Hemolytic Uremic Syndrome, Hereditary Angioedema, Paroxysmal Nocturnal Hemoglobinuria), Mechanism of Action (C1 Inhibitors) - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118495
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The landscape of oral complement inhibitors has witnessed a dramatic evolution as researchers and clinicians recognize the potential of small-molecule therapies to deliver targeted regulation of the complement cascade. With complexity inherent in complement-mediated disorders, the shift from parenteral to oral formulations represents a paradigm transformation, offering patients greater convenience, adherence, and quality of life. Novel molecules targeting key complement components are progressing through clinical pipelines, triggering a recalibration of R&D priorities across biotech and pharmaceutical organizations.

As the therapeutic promise of oral complement inhibitors takes shape, stakeholders must navigate intricate scientific, regulatory, and commercial factors. Continued collaboration among academic centers, biotech innovators, and regulatory agencies has catalyzed a more seamless translation of benchside discoveries to bedside care. At the same time, patient advocacy groups and specialty societies have elevated the importance of real-world evidence in demonstrating meaningful outcomes. Consequently, the era of oral complement inhibition is not only redefining treatment paradigms but also reshaping the ecosystem in which groundbreaking therapies emerge and reach the individuals who need them most.

Unveiling the Transformative Shifts Reshaping the Oral Complement Inhibitor Arena and Disrupting Conventional Therapeutic Paradigms

The oral complement inhibitor domain is undergoing transformative shifts driven by convergence of technological innovation, regulatory momentum, and an intensified focus on personalized care. Recent breakthroughs in medicinal chemistry have yielded highly selective small molecules capable of modulating complement pathways with greater precision. These innovations are paving the way for combination regimens that synergize with immune modulators and biologics, ultimately enhancing therapeutic efficacy.

Concurrently, regulatory bodies have initiated adaptive frameworks, streamlining protocols for first-in-class oral complement agents. This flexible approach encourages accelerated development while upholding rigorous safety standards, fostering a more agile environment for sponsors. Meanwhile, patient-centric strategies are increasingly integral, with decentralized trial designs and digital health tools facilitating remote monitoring of pharmacodynamic markers. As a result, stakeholders can capture deeper insights into treatment response and tailor intervention strategies in near real time. Taken together, these shifts are reshaping the competitive landscape, prompting organizations to reevaluate portfolio strategies and invest in cross-functional capabilities to stay ahead of emerging scientific and market trends.

Assessing the Far-Reaching Ramifications of the 2025 United States Tariff Regime on Oral Complement Inhibitor Supply Chains and Commercial Dynamics

The introduction of a revised U.S. tariff regime effective in 2025 has reverberated through global supply chains and commercial operations for oral complement inhibitors. Manufacturers and distributors are navigating elevated import costs for key precursors, coupled with intensified scrutiny of cross-border logistics. These constraints have prompted a renewed emphasis on near-shoring and regional manufacturing hubs, aimed at mitigating exposure to tariff fluctuations.

In response, strategic alliances between biopharma firms and contract development organizations have accelerated localization of critical synthesis and formulation processes. Procurement teams are renegotiating supplier agreements to secure preferential terms and ensure continuity of raw-material supply. Simultaneously, portfolio managers are recalibrating launch strategies, taking into account variable cost structures in core markets. Despite these challenges, adaptive pricing frameworks and collaborative reimbursement initiatives are emerging to preserve patient access and commercial viability. By proactively addressing tariff-driven complexities, industry leaders can safeguard resilience in a dynamic policy environment.

Leveraging Segment-Specific Insights Reveals Strategic Opportunities Across Therapeutic Applications and Mechanisms Guiding Oral Complement Inhibitor Development

A nuanced understanding of market segmentation reveals critical inflection points for oral complement inhibitor deployment across diverse patient and clinical settings. Under the umbrella of therapeutic application, rare complement-mediated disorders such as atypical hemolytic uremic syndrome exhibit distinct adult and pediatric treatment pathways, each demanding tailored dosing regimens, safety surveillance, and patient support programs. Similarly, hereditary angioedema interventions bifurcate into acute management and long-term prophylactic strategies, with each segment influencing formulary negotiations and payer engagement differently. Paroxysmal nocturnal hemoglobinuria, another key indication, requires discrete considerations around adult and pediatric cohorts, as developmental pharmacology and long-term safety profiles underpin clinical adoption and guideline integration.

From a mechanism-of-action perspective, the exclusive focus on C1 inhibitors underscores both the therapeutic promise and the competitive contours of this molecular class. Entities developing next-generation C1 modulators are prioritizing oral bioavailability and pharmacokinetic consistency, seeking to overcome limitations associated with injectables. By synthesizing insights across therapeutic and mechanistic axes, decision-makers can pinpoint opportunities to differentiate pipeline assets, optimize clinical trial designs, and engage stakeholders with targeted value propositions that resonate in each specialized segment.

Uncovering Regional Variances to Inform Tactical Approaches in Americas Europe Middle East Africa and Asia Pacific Oral Complement Therapy Adoption

Regional dynamics are foundational to the trajectory of oral complement inhibitor integration. In the Americas, advanced reimbursement frameworks and a robust clinical research infrastructure facilitate rapid evaluation of novel oral candidates. Strategic collaborations among academic medical centers, specialty clinics, and patient advocacy networks are accelerating patient recruitment and real-world data collection, driving early adoption curves in key markets.

Meanwhile, Europe, the Middle East, and Africa present a tapestry of regulatory paradigms and payer landscapes. Harmonization efforts across the European Union expedite centralized reviews, but localized pricing negotiations and health technology assessments influence market entry timelines. In the Middle East and Africa, evolving healthcare infrastructure and selective public-private partnerships are catalyzing access in urban centers while highlighting the need for tailored distribution strategies.

In the Asia-Pacific region, surging investment in biopharma R&D and growing emphasis on domestic manufacturing capacity are transforming the environment for oral complement inhibitors. Early engagement with regional regulatory authorities and strategic alliances with local partners are essential to navigate diverse approval pathways. Moreover, digital health initiatives are enhancing disease awareness and facilitating decentralized care models, bolstering adoption among healthcare providers and patients across this expansive region.

Profiling Leading Innovators and Emerging Players Shaping the Future Trajectory of Oral Complement Inhibitor Markets Through Strategic Innovations

Leading biopharma organizations and emerging biotech ventures are at the forefront of oral complement inhibitor innovation. Established players with proven portfolios in complement biology are optimizing their pipelines through strategic licensing agreements, targeted acquisitions, and co-development partnerships. These efforts enable rapid scaling of late-stage candidates while leveraging existing regulatory and commercial infrastructure.

At the same time, specialized biotech firms are harnessing novel chemistries and proprietary delivery platforms to differentiate their oral assets. Collaborations with experienced contract research and manufacturing organizations have streamlined preclinical and clinical activities, accelerating timelines without compromising quality. Companies that integrate multi-partner consortiums for real-world evidence generation are enhancing their competitive profiles, demonstrating a commitment to comprehensive value demonstration.

Collectively, the ecosystem is characterized by a balance of established leaders and nimble innovators, all vying to address the unmet needs of patients with complement-mediated disorders. By monitoring strategic moves such as equity investments, pipeline divestitures, and translational research alliances, stakeholders can anticipate shifts in the competitive hierarchy and align their own strategies with prevailing industry trends.

Actionable Strategies for Industry Leaders to Navigate Regulatory Complexities and Capitalize on Oral Complement Inhibitor Market Potential

To maintain a competitive advantage, industry leaders must deploy a multi-pronged strategy that reflects the complexity of the oral complement inhibitor landscape. First, aligning research and development initiatives with the most pressing unmet clinical needs will ensure that novel oral molecules address both efficacy and patient experience. Engaging early with regulators and payers through parallel scientific advice programs can streamline approval pathways and fortify reimbursement dossiers.

Second, strengthening supply chain resilience by diversifying manufacturing geographies and forging partnerships with regional contract providers will mitigate risks associated with tariff and regulatory fluctuations. Incorporating digital health capabilities, such as remote monitoring and patient support applications, can enhance adherence and generate real-world data to support long-term value narratives.

Third, cultivating collaborative alliances with patient advocacy groups and healthcare institutions will amplify educational efforts and foster trust in new oral therapies. Finally, adopting flexible pricing models that reflect differentiated segment needs and total cost-of-care benefits will facilitate market access across heterogeneous payer systems. Through these interventions, organizations can navigate regulatory complexities and capitalize sustainably on the growing promise of oral complement inhibition.

Employing Rigorous Multimodal Research Methodologies to Derive Actionable Insights in the Oral Complement Inhibitor Domain

This research employs a rigorous multimodal approach, integrating qualitative and quantitative methodologies to ensure comprehensive insight into the oral complement inhibitor domain. Primary research includes in-depth interviews with key opinion leaders in hematology, nephrology, and immunology, as well as discussions with regulatory affairs specialists and payers. These conversations illuminate evolving clinical practices, reimbursement considerations, and anticipated policy shifts.

Secondary research encompasses systematic reviews of peer-reviewed literature, clinical trial registries, regulatory filings, and proprietary patent databases. Data sourcing is supplemented by real-world evidence derived from specialty clinic registries, patient advocacy networks, and digital health platforms. Throughout the research process, data triangulation techniques validate findings, while an expert advisory panel reviews draft analyses to ensure relevance and accuracy.

By adhering to stringent quality control protocols, including cross-validation of sources and iterative feedback loops, the methodology delivers robust, actionable insights that reflect current trends and emerging opportunities in oral complement inhibition.

Concluding Insights Emphasizing Critical Trends and Strategic Imperatives with Evolving Clinical Considerations in the Oral Complement Inhibitor Landscape

In summation, the oral complement inhibitor landscape is undergoing a profound transformation driven by innovative science, adaptive regulatory frameworks, and shifting patient expectations. The convergence of targeted small-molecule development, advanced clinical trial designs, and regional dynamics underscores the importance of strategic agility. Segmentation insights reveal differentiated pathways across therapeutic indications and mechanisms, while tariff-driven supply chain adaptations highlight the need for resilient operational models.

Key industry players and agile innovators alike are positioning themselves through strategic partnerships, diversified pipelines, and real-world evidence generation. As the sector navigates complexity, actionable recommendations emphasize the value of early stakeholder engagement, dynamic pricing strategies, and integrated digital health solutions. Ultimately, organizations that harness these insights and align their strategies with evolving market imperatives will be best positioned to deliver transformative therapies and meet the unmet needs of patients with complement-mediated disorders.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Therapeutic Application
    • Atypical Hemolytic Uremic Syndrome
      • Adult Patients
      • Pediatric Patients
    • Hereditary Angioedema
      • Acute Treatment
      • Prophylactic Treatment
    • Paroxysmal Nocturnal Hemoglobinuria
      • Adult Patients
      • Pediatric Patients
  • Mechanism Of Action
    • C1 Inhibitors
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Novartis AG
  • AstraZeneca PLC
  • BioCryst Pharmaceuticals, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising preference for oral complement inhibitors in hereditary angioedema management strategies
5.2. Emergence of patient-centric digital adherence tools to support oral complement inhibitor regimens
5.3. Expansion of oral complement inhibitor clinical trials targeting geographic markets in Asia Pacific and Latin America
5.4. Strategic partnerships between biotech firms and pharma giants accelerating oral complement inhibitor commercialization
5.5. Healthcare payer negotiations intensifying over pricing and reimbursement of novel oral complement inhibitors
5.6. Integration of real-world evidence studies demonstrating long-term safety and efficacy of oral complement therapies
5.7. Advancements in molecular design improving selectivity and bioavailability of next-generation oral complement inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oral Complement Inhibitors Market, by Therapeutic Application
8.1. Introduction
8.2. Atypical Hemolytic Uremic Syndrome
8.2.1. Adult Patients
8.2.2. Pediatric Patients
8.3. Hereditary Angioedema
8.3.1. Acute Treatment
8.3.2. Prophylactic Treatment
8.4. Paroxysmal Nocturnal Hemoglobinuria
8.4.1. Adult Patients
8.4.2. Pediatric Patients
9. Oral Complement Inhibitors Market, by Mechanism Of Action
9.1. Introduction
9.2. C1 Inhibitors
10. Americas Oral Complement Inhibitors Market
10.1. Introduction
10.2. United States
10.3. Canada
10.4. Mexico
10.5. Brazil
10.6. Argentina
11. Europe, Middle East & Africa Oral Complement Inhibitors Market
11.1. Introduction
11.2. United Kingdom
11.3. Germany
11.4. France
11.5. Russia
11.6. Italy
11.7. Spain
11.8. United Arab Emirates
11.9. Saudi Arabia
11.10. South Africa
11.11. Denmark
11.12. Netherlands
11.13. Qatar
11.14. Finland
11.15. Sweden
11.16. Nigeria
11.17. Egypt
11.18. Turkey
11.19. Israel
11.20. Norway
11.21. Poland
11.22. Switzerland
12. Asia-Pacific Oral Complement Inhibitors Market
12.1. Introduction
12.2. China
12.3. India
12.4. Japan
12.5. Australia
12.6. South Korea
12.7. Indonesia
12.8. Thailand
12.9. Philippines
12.10. Malaysia
12.11. Singapore
12.12. Vietnam
12.13. Taiwan
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Analysis
13.3.1. Novartis AG
13.3.2. AstraZeneca PLC
13.3.3. BioCryst Pharmaceuticals, Inc.
14. ResearchAI
15. ResearchStatistics
16. ResearchContacts
17. ResearchArticles
18. Appendix
List of Figures
FIGURE 1. ORAL COMPLEMENT INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 10. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 12. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ORAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 18. ORAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 19. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHAI
FIGURE 20. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 21. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 22. ORAL COMPLEMENT INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ORAL COMPLEMENT INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 40. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 51. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 54. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 63. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 64. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 65. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 66. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 67. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 68. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 69. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 70. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 71. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 72. CANADA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 73. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 76. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 77. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 78. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 79. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 80. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 81. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 82. MEXICO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 118. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 125. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 126. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 127. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 128. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 129. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 130. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 131. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 132. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 133. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 134. GERMANY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 135. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 138. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 139. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 140. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 141. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 142. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 143. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 144. FRANCE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 145. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 148. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 149. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 150. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 155. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 158. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 159. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 160. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 161. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 162. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 163. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 164. ITALY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 165. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 166. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 167. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 168. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 169. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 170. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 171. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 172. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 173. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 174. SPAIN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 188. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 190. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 196. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 198. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 200. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 205. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 208. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 209. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 210. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 211. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 212. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 213. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 214. DENMARK ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 215. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 218. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 219. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 220. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 228. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 229. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 230. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 231. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 232. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 233. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 234. QATAR ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 235. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 238. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 239. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 240. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 241. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 242. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 243. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 244. FINLAND ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 245. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 248. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 249. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 250. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 255. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 258. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 259. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 260. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 268. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 269. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 270. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 271. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 272. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 273. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 274. EGYPT ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 275. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2024 (USD MILLION)
TABLE 278. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2025-2030 (USD MILLION)
TABLE 279. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2024 (USD MILLION)
TABLE 280. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2025-2030 (USD MILLION)
TABLE 281. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2024 (USD MILLION)
TABLE 282. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2025-2030 (USD MILLION)
TABLE 283. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 284. TURKEY ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 285. ISRAEL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
TABLE 286. ISRAEL ORAL COMPLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oral Complement Inhibitors market report include:
  • Novartis AG
  • AstraZeneca PLC
  • BioCryst Pharmaceuticals, Inc.

Related Topics

Related Reports

Complement Inhibitors Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Complement Inhibitors Market by Product Type, Indication, Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025 - Product Image

Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Complement Inhibitors - Pipeline Insight, 2025 - Product Image

Complement Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 150 Pages
  • Global
From
Complement C5 Inhibitors - Pipeline Insight, 2025 - Product Image

Complement C5 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.